Courtney Thornburg
Pediatric Hematology-Oncology · San Diego, CANPI 1538222310
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.2%), speaking fees and grants — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Genentech USA, Inc. at 34.7% of the total. Reporting peaked in 2023 at $59,391 and has fallen 99.9% since, to $34 in 2025. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $1496.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$46K
- Novo Nordisk$21K
- Sanofi$19K
- CSL Behring$15K
- Spark Therapeutics, Inc.$11K
- Biomarin Pharmaceutical Inc.$9K
- plus $12K from 11 others
Across 233 payments — averaging $1173.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$147K
- Biomarin Pharmaceutical Inc.$56K
- Bayer$43K
- Sanofi US Services Inc.$19K
- Regeneron$7K
- Bioverativ Therapeutics Inc.$1K
What the payments were for
- Consulting fees$72,66355%
- Speaking & faculty fees$31,28324%
- Grants$19,80015%
- Travel & lodging$4,1613%
- Food & beverage$2,6532%
- Education$1,1701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 30 | $45,771 |
| Novo Nordisk | 2 | $20,880 |
| Sanofi | 13 | $18,607 |
| CSL Behring | 12 | $14,677 |
| Spark Therapeutics, Inc. | 6 | $10,526 |
| Biomarin Pharmaceutical Inc. | 6 | $9,448 |
| Regeneron | 5 | $7,094 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,913 |
| Pfizer | 4 | $1,565 |
| Octapharma USA, Inc. | 1 | $600 |
| Genetix Biotherapeutics Inc | 1 | $225 |
| AstraZeneca | 2 | $153 |
| Agios Pharmaceuticals, Inc. | 1 | $115 |
| Genentech, Inc. | 1 | $94 |
| Boston Scientific | 1 | $28 |
| Bayer | 1 | $19 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,730 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in San Diego
- Julie JaffraySan Diego$90K
- Jennifer YuSan Diego$19K
- Hilda DingSan Diego$17K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.